Research
Energy balance
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more.
Cagrilintide-semaglutide may be particularly effective for achieving clinically significant weight loss.
StrongSupportsmedium confidence
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001).
Why this rating
Based on the robust trial design and statistical significance.
Source
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Melanie J. Davies et al. · New England Journal of Medicine · 2025
rct · n=1206Cited 78×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →